Navigation Links
Patients use OTC NSAIDs even when they have a high risk of serious side effects
Date:6/12/2013

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint.

Of these high risk OTC NSAID users, over one-third had taken the medication for more than 7 days, and 3% had exceeded the maximum recommended daily dosage.

Patients were considered at high risk of a serious ADE from OTC NSAIDs if they had a history of a peptic ulcer or ulcer complication, myocardial infarction, stroke or heart failure, were aged over 70 years, had a glomerular filtration rate < 30ml/L, or had a combination of two or more of the following: use of an anticoagulant, aspirin, corticosteroid or selective serotonin reuptake inhibitor; age 60-70 years; history of severe rheumatoid arthritis or diabetes mellitus.

Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressure and worsening heart failure.

"NSAIDs tend to be regarded by patients as harmless painkillers. However, in reality, even those available over the counter can cause a number of unpleasant side effects," said lead author of the study Aafke Koffeman of the Department Of General Practice, Erasmus Medical Center, Rotterdam, Netherlands.

"In most cases, it is likely to be ignorance of these potential ADEs rather than a deliberate disregard of the risks and contraindications", Ms Koffeman speculated. "These new data highlight the importance of healthcare professionals continuing to inform their patients of the risks of taking OTC NSAIDs, particularly where a new diagnosis or prescription increases their individual risk. High risk patients with painful musculoskeletal complaints should be advised to take safer alternative painkillers," she concluded.

Complications from the use of NSAIDs by high risk patients are a common cause of unplanned hospital admissions related to medications, which in turn constitute a significant public health problem. Two previous Dutch observational studies have shown that approximately 5% of all unplanned hospital admissions are associated with ADEs, of which 40-46% are potentially preventable.2

This study was among adults registered with four Dutch general practitioners (GPs). Two samples of different patient populations were selected: (i) a random sample of adults (general population), and (ii) a sample of adult patients with a high risk of developing a serious ADE from NSAID use (high-risk population).

Patients' risk profiles were determined using their electronic medical records. All included patients were sent a questionnaire regarding their use of OTC NSAIDs in the four weeks prior to participation. In the high-risk population, of the 265 patients who agreed to participate, 33 (13%) had used an OTC NSAID. In the general population sample, of the 120 patients who agreed to participate, 35 (29%) had used an OTC NSAID.

Over 30% of OTC NSAID users had used the treatment for more than seven days in the high risk-population, and over 20% in the general population. OTC NSAIDs were used in a dosage exceeding the recommended daily maximum dose by 3% and 9% in the high-risk and the general populations respectively.

Musculoskeletal complaints formed the most commonly cited reason for OTC NSAID use in the high-risk group; 67% gave this as a reason for use.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related biology news :

1. Exercise for stroke patients brains
2. Experts find epigenetic changes moderate reality distortion in schizophrenia patients
3. Study finds taking probiotics has benefits for patients in hospitals
4. Oncologists are stressed and have difficulty discussing death with patients -- Ben-Gurion U. study
5. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
6. Nanomedicines impact on patients under the microscope
7. Vitamin C does not lower uric acid levels in gout patients
8. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
9. AegisCare Offers Specialized Home Health Care for Dementia and Alzheimers Patients
10. University of Maryland Medical Center launches genetic-testing program for cardiac patients
11. Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... 2017 , ... Each year, Crain’s Detroit Business News ranks the most innovative ... patent estate of a company, its impact and significance, and the likelihood of bringing ... in technologies that transform energy sources such as low dose X-ray and convert them ...
(Date:1/12/2017)... Colo (PRWEB) , ... January 12, 2017 , ... ... then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few ... describes a new drug combination that has stabilized Rosendahl’s disease and increased both ...
(Date:1/12/2017)... PORTLAND, Oregon and Pune, India , January 12, 2017 ... In vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis ... reach $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase ... show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ ... treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from ...
Breaking Biology Technology: